Disclosures for "RESCUE: A Proof-of-Concept Trial with Adjunct RNS60 Treatment Shows Safety, Reduced Infarct Growth, and Numerical Improvement in all Prespecified Efficacy Endpoints in Participants with Acute Ischemic Stroke "
-
Dr. Ghosh has received personal compensation for serving as an employee of Revalesio Corporation.
-
Dr. Dubow has received personal compensation in the range of $100,000-$499,999 for serving as a Consultant for Revalesio .
-
Jocelyn Sutherland has received personal compensation for serving as an employee of Revalesio.
-
Author has nothing to disclose
-
Wendy Smith has nothing to disclose.
-
Dr. Chiu has nothing to disclose.
-
Dr. Clark has nothing to disclose.
-
The institution of Dr. Favilla has received research support from National Institutes of Health. The institution of Dr. Favilla has received research support from American Heart Association. The institution of Dr. Favilla has received research support from OpenWater, Inc..
-
Mr. Ansari has nothing to disclose.
-
Dr. Kalmes has received personal compensation for serving as an employee of Revalesio.
-
Jarrad Mock has received personal compensation for serving as an employee of Revalesio.
-
Douglas Cook has nothing to disclose.
-
Author has nothing to disclose
-
Author has nothing to disclose
-
Author has nothing to disclose
-
Krisztina Moldovan has nothing to disclose.
-
Radmehr Torabi has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Silk Road Medical.
-
Dr. Liebeskind has received research support from Cerenovus. Dr. Liebeskind has received research support from Genentech . Dr. Liebeskind has received research support from Medtronic. Dr. Liebeskind has received research support from Stryker.
-
Author has nothing to disclose